A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 5, 2013, Pages 799-803

  Ponce, Doris M ^a,b   Sauter, Craig ^a,b   Devlin, Sean ^a   Lubin, Marissa ^a   Gonzales, Anne Marie ^a   Kernan, Nancy A ^a   Scaradavou, Andromachi ^a   Giralt, Sergio ^a,b   Goldberg, Jenna D ^a,b   Koehne, Guenther ^a,b   Perales, Miguel A ^a,b   Young, James W ^a,b   Castro Malaspina, Hugo ^a,b   Jakubowski, Ann ^a,b   Papadopoulos, Esperanza B ^a,b   Barker, Juliet N ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute leukemia; Allogeneic transplant; Comorbidity score; Cord blood

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MYELODYSPLASTIC SYNDROME; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUTROPHIL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; SORROR COMORBIDITY SCORE; THROMBOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPHILS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84876329212     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.007     Document Type: Article

References (33)

1. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
2. Ponce D.M., Zheng J., Gonzales A.M., et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1316-1326.
3. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003, 102:1915-1919.
4. Brunstein C., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after non-myeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007, 110:3064-3070.
5. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:659-667.
6. Uchida N., Wake A., Takagi S., et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008, 14:583-590.
7. Oran B., Wagner J.E., DeFor T.E., et al. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2011, 17:1327-1334.
8. Brunstein C.G., Eapen M., Ahn K.W., et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012, 119:5591-5598.
9. Majhail N.S., Brunstein C.G., Shanley R., et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 2012, 47:494-498.
10. Brunstein C.G., Weisdorf D.J., Defor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
11. Cohen J., Gandhi M., Naik P., et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005, 129:229-239.
12. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
13. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
14. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
15. Rodrigues C.A., Sanz G., Brunstein C.G., et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009, 27:256-263.
16. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
17. Kindwall-Keller T.L., Hegerfeldt Y., Meyerson H.J., et al. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012, 47:924-933.
18. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
19. Jacobson P.A., Huang J., Wu J., et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2010, 16:421-429.
20. Barker J.N., Byam C., Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011, 117:2332-2339.
21. Barker J.N., Abboud M., Rice R.D., et al. A " no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant 2009, 15:1596-1602.
22. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
23. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
24. Sauter C., Abboud M., Jia X., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011, 17:1460-1471.
25. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
26. Ciurea S., Saliba R., Hamerschlak N. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymph 2012, 53:901-906.
27. Delaney C., Gutman J.A., Appelbaum F.R. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009, 147:207-216.
28. de Lima M., McNiece I., Robinson S.N., et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. New Engl. J. Med 2012, 367:2305-2315.
29. Delaney C., Heimfeld S., Brashem-Stein C., et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
30. Bautista G., Cabrera J.R., Regidor C., et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009, 43:365-373.
31. Liu H., Rich E.S., Godley L., et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011, 118:6438-6445.
32. Raimondi R., Tosetto A., Oneto R., et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 2012, 120:1327-1333.
33. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.